Danaher Co. (NYSE:DHR) Shares Bought by GenTrust LLC

GenTrust LLC raised its stake in shares of Danaher Co. (NYSE:DHR) by 40.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,655 shares of the conglomerate’s stock after purchasing an additional 760 shares during the quarter. GenTrust LLC’s holdings in Danaher were worth $739,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DHR. Legal & General Group Plc boosted its position in Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after buying an additional 139,989 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock worth $849,195,000 after acquiring an additional 85,081 shares during the period. Swedbank AB purchased a new position in shares of Danaher during the first quarter worth $676,545,000. Finally, Blair William & Co. IL lifted its position in Danaher by 0.9% during the second quarter. Blair William & Co. IL now owns 1,777,030 shares of the conglomerate’s stock valued at $443,991,000 after purchasing an additional 15,766 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE DHR opened at $235.83 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company has a market cap of $170.34 billion, a PE ratio of 45.01, a price-to-earnings-growth ratio of 4.32 and a beta of 0.85. The stock’s 50 day simple moving average is $258.15 and its 200-day simple moving average is $259.88.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. UBS Group decreased their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.